EMFAT
BBIO icon

Emerald Mutual Fund Advisers Trust’s BridgeBio Pharma BBIO Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Sell
18,741
-301,470
-94% -$21.1M 0.05% 141
2026
Q1 		$23.8M Buy
320,211
+3,427
+1% +$248K 1.15% 21
2025
Q4 		$24.2M Sell
316,784
-94,643
-23% -$6.21M 1.18% 21
2025
Q3 		$21.4M Sell
411,427
-234,318
-36% -$11.4M 1.1% 27
2025
Q2 		$27.9M Sell
645,745
-78,609
-11% -$2.86M 1.7% 9
2025
Q1 		$25M Sell
724,354
-518
-0.1% -$17.5K 1.78% 10
2024
Q4 		$19.9M Sell
724,872
-26,483
-4% -$684K 1.21% 27
2024
Q3 		$19.1M Buy
751,355
+253,101
+51% +$6.64M 0.99% 36
2024
Q2 		$12.6M Sell
498,254
-2,000
-0.4% -$54.7K 0.66% 55
2024
Q1 		$15.5M Hold
500,254
– – 0.81% 48
2023
Q4 		$20.2M Hold
500,254
– – 1.07% 28
2023
Q3 		$13.2M Buy
500,254
+104,714
+26% +$2.97M 0.8% 55
2023
Q2 		$6.8M Buy
+395,540
New +$5.95M 0.37% 96

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's BBIO Position: Q2 2026 in Review

Emerald Mutual Fund Advisers Trust reduced its BridgeBio Pharma (BBIO) stake by 94% in Q2 2026, selling an estimated $21.1M and leaving 18,741 shares worth $1.4M. The position accounts for 0.05% of the portfolio, ranked #141.

Emerald Mutual Fund Advisers Trust first reported a position in BBIO in Q2 2023 and has held it in 13 quarters since. The position peaked at $27.9M in Q2 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Emerald Mutual Fund Advisers Trust held 18,741 shares of BridgeBio Pharma worth $1.4M as of Q2 2026.
  • Emerald Mutual Fund Advisers Trust sold 301,470 BridgeBio Pharma shares in Q2 2026, an estimated $21.1M.
  • BridgeBio Pharma made up 0.05% of Emerald Mutual Fund Advisers Trust's portfolio in Q2 2026, its #141 holding.
  • Emerald Mutual Fund Advisers Trust first reported a position in BridgeBio Pharma in Q2 2023 and has held it in 13 quarters since.
  • Emerald Mutual Fund Advisers Trust's BridgeBio Pharma position peaked at $27.9M in Q2 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2026, filed 5 Aug 2026.